Literature DB >> 1551543

Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome.

G M Forbes1, G P Jeffrey, K B Shilkin, W D Reed.   

Abstract

Serious carbamazepine hepatotoxicity is being recognized more frequently and is usually manifest as an acute granulomatous hepatitis that is self-limiting if the drug is withdrawn. The case of a 59-year-old man who developed the vanishing bile duct syndrome after 2 months of treatment with carbamazepine for glossopharyngeal neuralgia is reported. The characteristic histological features of this syndrome may also be seen in primary biliary cirrhosis, primary sclerosing cholangitis, graft-vs.-host disease after allogeneic bone marrow transplantation, chronic liver allograft rejection, and other drug reactions. The progress of this patient to date suggests that irreversible liver injury resulting in chronic liver disease is likely, in keeping with the clinical course of the vanishing bile duct syndrome in most cases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551543

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

1.  Efficacy of early immunosuppressive therapy in a child with carbamazepine-associated vanishing bile duct and Stevens-Johnson syndromes.

Authors:  Monica Garcia; Maroun J Mhanna; Moon-Ja Chung-Park; Pamela H Davis; Maya D Srivastava
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

2.  Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.

Authors:  Matthew Mason; Oyedele Adeyi; Scott Fung; Barbara-Ann Millar
Journal:  BMJ Case Rep       Date:  2014-11-28

3.  Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.

Authors:  Herbert L Bonkovsky; David E Kleiner; Jiezhun Gu; Joseph A Odin; Mark W Russo; Victor M Navarro; Robert J Fontana; Marwan S Ghabril; Huiman Barnhart; Jay H Hoofnagle
Journal:  Hepatology       Date:  2017-02-07       Impact factor: 17.425

4.  A Case of Carbamazepine-induced Severe Cholestatic Hepatitis: Case Report and Review of Literature.

Authors:  Suhas Ganesh; Lekhansh Shukla; Arun Kandasamy; Vivek Benegal
Journal:  Indian J Psychol Med       Date:  2017 Sep-Oct

Review 5.  Drug-induced cholestasis.

Authors:  Vinay Sundaram; Einar S Björnsson
Journal:  Hepatol Commun       Date:  2017-09-11

6.  Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case report.

Authors:  Wen Xie; Qi Wang; Yuanjiao Gao; Calvin Q Pan
Journal:  BMC Gastroenterol       Date:  2018-09-29       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.